JPWO2020264083A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264083A5 JPWO2020264083A5 JP2022541772A JP2022541772A JPWO2020264083A5 JP WO2020264083 A5 JPWO2020264083 A5 JP WO2020264083A5 JP 2022541772 A JP2022541772 A JP 2022541772A JP 2022541772 A JP2022541772 A JP 2022541772A JP WO2020264083 A5 JPWO2020264083 A5 JP WO2020264083A5
- Authority
- JP
- Japan
- Prior art keywords
- biotin
- streptavidin
- interference
- qsav
- beads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010090804 Streptavidin Proteins 0.000 claims description 419
- 239000011616 biotin Substances 0.000 claims description 405
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 393
- 229960002685 biotin Drugs 0.000 claims description 379
- 235000020958 biotin Nutrition 0.000 claims description 364
- 239000011324 bead Substances 0.000 claims description 285
- 239000003153 chemical reaction reagent Substances 0.000 claims description 148
- 238000004166 bioassay Methods 0.000 claims description 136
- 102000004965 antibodies Human genes 0.000 claims description 121
- 108090001123 antibodies Proteins 0.000 claims description 121
- 239000000523 sample Substances 0.000 claims description 121
- 230000001745 anti-biotin Effects 0.000 claims description 95
- 230000000903 blocking Effects 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 30
- 102000038129 antigens Human genes 0.000 claims description 30
- 108091007172 antigens Proteins 0.000 claims description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 22
- 230000021615 conjugation Effects 0.000 claims description 20
- 239000011859 microparticle Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 18
- 230000002776 aggregation Effects 0.000 claims description 17
- 238000004220 aggregation Methods 0.000 claims description 14
- 238000003018 immunoassay Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000007413 biotinylation Methods 0.000 claims description 10
- 230000002829 reduced Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 7
- 230000000116 mitigating Effects 0.000 claims description 7
- 230000001268 conjugating Effects 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000006011 modification reaction Methods 0.000 claims description 5
- 230000001404 mediated Effects 0.000 claims description 4
- 230000003612 virological Effects 0.000 claims description 4
- YMXHPSHLTSZXKH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-UHFFFAOYSA-N 0.000 claims description 3
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 238000002967 competitive immunoassay Methods 0.000 claims description 3
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 230000000890 antigenic Effects 0.000 claims 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 48
- 108090001095 Immunoglobulin G Proteins 0.000 description 48
- 239000000243 solution Substances 0.000 description 40
- 229920001223 polyethylene glycol Polymers 0.000 description 38
- 241000283707 Capra Species 0.000 description 30
- 238000001514 detection method Methods 0.000 description 27
- 239000008188 pellet Substances 0.000 description 22
- 238000005406 washing Methods 0.000 description 22
- 239000002202 Polyethylene glycol Substances 0.000 description 21
- 239000012491 analyte Substances 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 238000007792 addition Methods 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 235000000638 D-biotin Nutrition 0.000 description 16
- 239000011665 D-biotin Substances 0.000 description 16
- 210000002966 Serum Anatomy 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 230000002452 interceptive Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000002122 magnetic nanoparticle Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 12
- 239000011550 stock solution Substances 0.000 description 12
- 239000003656 tris buffered saline Substances 0.000 description 12
- 240000004958 Talinum portulacifolium Species 0.000 description 11
- 235000001211 Talinum portulacifolium Nutrition 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 150000003141 primary amines Chemical class 0.000 description 11
- 239000006226 wash reagent Substances 0.000 description 11
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 10
- 239000012131 assay buffer Substances 0.000 description 9
- 230000002860 competitive Effects 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000010791 quenching Methods 0.000 description 9
- 239000012465 retentate Substances 0.000 description 9
- -1 samples Substances 0.000 description 9
- 238000001542 size-exclusion chromatography Methods 0.000 description 9
- 125000003396 thiol group Chemical class [H]S* 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000003247 decreasing Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 230000000171 quenching Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- 210000002381 Plasma Anatomy 0.000 description 6
- 239000005092 Ruthenium Substances 0.000 description 6
- 239000002981 blocking agent Substances 0.000 description 6
- 239000007771 core particle Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229910052707 ruthenium Inorganic materials 0.000 description 6
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000002820 assay format Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001685 Thyroid Gland Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000779 depleting Effects 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 108010045030 monoclonal antibodies Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000012536 storage buffer Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 229920002395 Aptamer Polymers 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 229930003756 Vitamin B7 Natural products 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical class C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 150000001615 biotins Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 230000002572 peristaltic Effects 0.000 description 3
- 108091008117 polyclonal antibodies Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000006177 thiolation reaction Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000011912 vitamin B7 Nutrition 0.000 description 3
- 239000011735 vitamin B7 Substances 0.000 description 3
- 229930003231 vitamins Natural products 0.000 description 3
- WWVANQJRLPIHNS-BKPPORCPSA-N 2-Iminobiotin Chemical compound N1C(=N)N[C@H]2[C@H](CCCCC(=O)O)SC[C@H]21 WWVANQJRLPIHNS-BKPPORCPSA-N 0.000 description 2
- LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3aS,4S,6aR)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920002301 Cellulose acetate Polymers 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 229920000344 Molecularly imprinted polymer Polymers 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 229940088594 Vitamin Drugs 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004164 analytical calibration Methods 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 108010043595 captavidin Proteins 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 238000007374 clinical diagnostic method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002101 lytic Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012070 reactive reagent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000001502 supplementation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- IEQCYZWTGGUSAV-XYPYZODXSA-N C1(CCC(N1[C@@H]1CC[C@H](CC1)CN1C(C=CC1=O)=O)=O)=O Chemical compound C1(CCC(N1[C@@H]1CC[C@H](CC1)CN1C(C=CC1=O)=O)=O)=O IEQCYZWTGGUSAV-XYPYZODXSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 240000002275 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 210000004209 Hair Anatomy 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010012104 Heterophile Antibodies Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229940121658 Medical Device Drugs 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- JJAHTWIKCUJRDK-XYPYZODXSA-N O=C([C@@H]1CC[C@@H](CN2C(C=CC2=O)=O)CC1)ON1C(=O)CCC1=O Chemical compound O=C([C@@H]1CC[C@@H](CN2C(C=CC2=O)=O)CC1)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-XYPYZODXSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 240000007742 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 102100016435 TNNI3 Human genes 0.000 description 1
- 101700006104 TNNI3 Proteins 0.000 description 1
- 229940036555 Thyroid hormones Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004931 aggregating Effects 0.000 description 1
- 230000002009 allergen Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108091022036 biotin-binding proteins Proteins 0.000 description 1
- 102000028710 biotin-binding proteins Human genes 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000410 poly[9,9-bis((6'-N,N,N-trimethylammonium)hexyl)fluorenylene phenylene dibromide] polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866318P | 2019-06-25 | 2019-06-25 | |
| US62/866,318 | 2019-06-25 | ||
| US202063006630P | 2020-04-07 | 2020-04-07 | |
| US63/006,630 | 2020-04-07 | ||
| PCT/US2020/039503 WO2020264083A1 (en) | 2019-06-25 | 2020-06-25 | Compositions and methods for detecting and depleting sample interferences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022539919A JP2022539919A (ja) | 2022-09-13 |
| JPWO2020264083A5 true JPWO2020264083A5 (zh) | 2022-11-14 |
Family
ID=74062043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541772A Pending JP2022539919A (ja) | 2019-06-25 | 2020-06-25 | サンプル干渉を検出および枯渇させるための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220252586A1 (zh) |
| EP (1) | EP3990921A4 (zh) |
| JP (1) | JP2022539919A (zh) |
| CN (1) | CN114286941A (zh) |
| AU (1) | AU2020308574A1 (zh) |
| CA (1) | CA3152057A1 (zh) |
| IL (1) | IL291075A (zh) |
| WO (1) | WO2020264083A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117813508A (zh) * | 2021-08-10 | 2024-04-02 | 万迈医疗仪器有限公司 | 在基于干涉测量法的生化测定中使用生物素包被的固体支持物的方法 |
| CN116047087B (zh) * | 2022-12-29 | 2023-07-25 | 宁波瑞源生物科技有限公司 | 一种判断样本中游离生物素的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102257912B1 (ko) * | 2013-03-13 | 2021-05-27 | 메소 스케일 테크놀러지즈, 엘엘시 | 개선된 분석 방법 |
| EP3176580A1 (en) * | 2015-12-01 | 2017-06-07 | Roche Diagnostics GmbH | Method for reduction of interferences in immunoassays |
| US10948484B2 (en) * | 2016-04-11 | 2021-03-16 | Veravas, Inc. | Sample depletion and enrichment to improve the quality of diagnostic test results |
-
2020
- 2020-06-25 EP EP20833331.0A patent/EP3990921A4/en active Pending
- 2020-06-25 US US17/636,012 patent/US20220252586A1/en active Pending
- 2020-06-25 JP JP2022541772A patent/JP2022539919A/ja active Pending
- 2020-06-25 CN CN202080060085.6A patent/CN114286941A/zh active Pending
- 2020-06-25 AU AU2020308574A patent/AU2020308574A1/en active Pending
- 2020-06-25 CA CA3152057A patent/CA3152057A1/en active Pending
- 2020-06-25 WO PCT/US2020/039503 patent/WO2020264083A1/en unknown
-
2022
- 2022-03-02 IL IL291075A patent/IL291075A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10761091B2 (en) | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples | |
| CN108362688B (zh) | 一种25羟基维生素d磁微粒化学发光检测试剂盒 | |
| CN113710365B (zh) | 用于在免疫测定中重复使用半抗原涂覆的探针的方法 | |
| US20220252586A1 (en) | Compositions and methods for detecting and depleting sample interferences | |
| CN112823048A (zh) | 消除和富集的方法 | |
| KR920000057B1 (ko) | 특이적으로 결합가능한 물질의 측정 방법 및 시약 | |
| CN108362895B (zh) | 叶酸检测试剂盒及其制备方法 | |
| US6800608B2 (en) | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator | |
| EP3511712B1 (en) | Method for measuring thyroglobulin | |
| JPWO2020264083A5 (zh) | ||
| US9891214B2 (en) | Immunological assay method | |
| US6927071B2 (en) | Method for reducing non-specific aggregation of latex microparticles in the presence of serum or plasma | |
| CN109358192B (zh) | 一种去除抗药抗体检测样品中游离药物的装置和方法、该装置的制备方法及应用 | |
| US20030138974A1 (en) | Tertiary amine compounds for use in immunoassays | |
| JPH0727764A (ja) | Ｆｃ部位をブロックした免疫学的測定用抗体、該抗体を含む免疫学的測定用試薬、該免疫学的測定用試薬を使用する免疫学的測定法及びＦｃ部位をブロックするブロック試薬 | |
| JP2509840B2 (ja) | 免疫測定法及び免疫測定用試薬キット | |
| JP2020530852A (ja) | 抗体コンジュゲーション方法 | |
| CN117030997B (zh) | 一种小分子化合物的均相免疫分析方法 | |
| JPH04329357A (ja) | 免疫学的測定方法 | |
| JP2688943B2 (ja) | 試料中の物質の測定方法 | |
| CN111337664A (zh) | 一种中性粒细胞明胶相关脂质运载蛋白检测试剂盒及用法 | |
| JPH0346565A (ja) | 磁性体を利用した酵素免疫測定法 | |
| JP2004117068A (ja) | 免疫測定試薬および免疫測定方法 | |
| CN115166264A (zh) | 一种铁调素检测试剂盒及其制备方法 | |
| JPH0560757A (ja) | 抗原の定量法及び抗原定量用免疫試薬 |